经蝶手术后失败的库欣病单次放射外科治疗:回顾性单中心队列研究
该回顾性单中心队列纳入186例经至少1次经蝶手术、随访≥12个月的残留或复发库欣病成人患者,评估单次伽玛刀放射外科的内分泌控制、影像学反应与毒性。24小时尿游离皮质醇(UFC)正常化者152例(81.7%),其中134例(72.0%)停用所有药物;停药后持久控制的累积发生率12个月为51%(95%CI:44-58%),120个月为64%(95%CI:56-71%)。作者结论为约三分之二患者可获得持久停药控制,肿瘤控制良好,但存在有意义的延迟性内分泌毒性,需长期监测。
要点
- 单次SRS后UFC正常化152/186例(81.7%),134例(72.0%)停用所有药物。
- 停药持久控制累积发生率12个月51%(95%CI:44-58%),120个月64%(95%CI:56-71%)。
- TSS至SRS间隔<6个月独立预测更高持久控制(P<.001);基线晨皮质醇更高(P<.001)、全蝶鞍治疗(P=.013)、女性(P=.027)预测更低持久控制。
核心结论
- 单次SRS可使约三分之二残留或复发库欣病患者获得持久停药的内分泌控制,肿瘤控制良好,但存在有意义的延迟性内分泌毒性,需长期监测。
研究设计与样本
- 回顾性单中心队列研究,时间跨度1990-2026年,中位内分泌随访54个月,单中心学术三级转诊中心。
- 纳入186例经≥1次经蝶手术、随访≥12个月的残留或复发库欣病成人患者;中位年龄40.8岁,女性占78.0%。
- 干预为单次头架固定立体定向放射外科,中位处方剂量23.0 Gy,最大剂量48.0 Gy。
- 预设主要结局为停用药物后的持久生化控制(持续24小时UFC正常化且未使用降皮质醇治疗),采用竞争风险方法建模。
主要发现
- UFC正常化152例(81.7%),其中停用所有药物者134例(72.0%)。
- 停药后持久控制的累积发生率12个月为51%(95%CI:44-58%),120个月为64%(95%CI:56-71%)。
- 新发内分泌病120个月累积发生率为42%(95%CI:32-52%);新发视野缺损为3.2%。
- TSS至SRS间隔<6个月独立预测更高持久控制(P<.001)。
- 基线晨皮质醇更高(P<.001)、全蝶鞍治疗(P=.013)和女性(P=.027)独立预测更低持久控制;更高的最大剂量是新发内分泌病唯一独立预测因素(P=.009)。
关键数值与推荐
- 中位处方剂量23.0 Gy,最大剂量48.0 Gy。
- 持久停药控制累积发生率:12个月51%(95%CI:44-58%),120个月64%(95%CI:56-71%)。
- 新发内分泌病120个月累积发生率42%(95%CI:32-52%),新发视野缺损3.2%。
临床怎么用
- 原文结论指出单次SRS可使约三分之二残留或复发库欣病患者获得持久停药控制,肿瘤控制良好,并指出有意义的延迟性内分泌毒性需长期监测。
局限性
- 原文报告为回顾性单中心队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Cushing disease (CD) from an adrenocorticotropic hormone-secreting pituitary adenoma causes substantial morbidity when hypercortisolism persists or recurs after transsphenoidal surgery (TSS). OBJECTIVE: To define endocrine control, radiographic response, toxicity, and predictors after single-session Gamma Knife radiosurgery for residual or recurrent CD. DESIGN: Retrospective single-center cohort study, 1990-2026; median endocrine follow-up 54 months. SETTING: Single academic tertiary referral center. PATIENTS: 186 adults with residual or recurrent CD after ≥1 TSS and ≥12 months of follow-up. Median age 40.8 years; 78.0% female. INTERVENTION: Single-session frame-based SRS (median prescription dose 23.0 Gy; maximum dose 48.0 Gy). MAIN OUTCOME MEASURES: Prespecified primary outcome was durable biochemical control off medications (sustained 24-hour urinary free cortisol [UFC] normalization without cortisol-lowering therapy), modeled with competing-risks methodology. RESULTS: UFC normalized in 152 patients (81.7%), including 134 (72.0%) off all medications. Cumulative incidence of durable off-medication control was 51% (95% CI: 44-58%) at 12 months and 64% (95% CI: 56-71%) at 120 months. New endocrinopathy reached 42% (95% CI: 32-52%) at 120 months; new visual deficit occurred in 3.2%. A TSS-to-SRS interval <6 months independently predicted higher durable control (P < .001), while higher baseline AM cortisol (P < .001), whole-sella treatment (P = .013), and female gender (P = .027) predicted lower durable control. Higher maximum dose was the sole independent predictor of new endocrinopathy (P = .009). CONCLUSION: Single-session SRS achieves durable medication-free control in approximately two-thirds of patients with residual or recurrent CD, with excellent tumor control and meaningful delayed endocrine toxicity warranting long-term surveillance.
引用
- Hajikarimloo B, Tos SM, Shinya Y, et al. Single-session radiosurgery for Cushing disease after failed resection: a retrospective single-center cohort study. J Clin Endocrinol Metab. 2026. PMID: 43006778. doi:10.1210/clinem/dgag369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。